Summit Therapeutics PLC (SMMT NASDAQ) stock market data APIs
$17.111
0.57(3.3%)
as of December 17, 2025
Try our APIs with
free plan!
Summit Therapeutics PLC Financial Data Overview
Price chart is built with
Anychart
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.
Prev. Close
17.111
Open
17.6777
High
17.754
Low
17.1018
52 wk Range
15.55-36.91
Market Cap
12 663 M
Shares Outstanding
744 M
EPS
-0.2315
Beta
-1.531
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Summit Therapeutics PLC (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Summit Therapeutics PLC data using free add-ons & libraries
Get Summit Therapeutics PLC Fundamental Data
Summit Therapeutics PLC Fundamental data includes:
- Net Revenue:
- EBITDA: -934 987 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-28
- EPS/Forecast: -0.1032
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Summit Therapeutics PLC News
New
Pfizer Issues Soft 2026 View: What Does It Mean for the Stock's Future?
Shares of Pfizer PFE dropped more than 3% on Tuesday after the company announced its financial outlook for the full year 2026, which fell short of investor expectations. The company is expected to hav...
Citi Asserts Buy Rating on Summit Therapeutics Inc. (SMMT) on Pipeline Development
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best biotech stocks to buy according to Wall Street analysts. On December 4, Citi analyst Yigal Nochomovitz reiterated a Buy rating on Summit Thera...
Has Summit Therapeutics Rally Left Enough Upside After 448.6% Surge and DCF Upswing?
Wondering if Summit Therapeutics at around $17.94 is still a smart bet or if most of the upside has already been captured? You are not alone, and that is exactly what we are going to unpack. In the sh...
2 Stocks Up Over 600% in the Past 3 Years With More Room to Run
Key Points Summit Therapeutics has an incredibly promising cancer candidate in the pipeline. Madrigal Pharmaceuticals made a breakthrough that could drive strong results for years to come. 10 stocks...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
